Cargando…

Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery

Introduction  The United States ranks 27th among nations worldwide for infant mortality with a rate of 6.1 deaths per 1,000 live births. The majority of perinatal morbidity and mortality is related to preterm birth, defined as delivery prior to 37 weeks' gestation. Among the risk factors for pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuponcic, Jacqueline, Cottrell, Connie, Lavin, Justin, Facchini, Wendy, Li, Marissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical Publishers 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702025/
https://www.ncbi.nlm.nih.gov/pubmed/31435484
http://dx.doi.org/10.1055/s-0039-1688776
_version_ 1783445153872084992
author Zuponcic, Jacqueline
Cottrell, Connie
Lavin, Justin
Facchini, Wendy
Li, Marissa
author_facet Zuponcic, Jacqueline
Cottrell, Connie
Lavin, Justin
Facchini, Wendy
Li, Marissa
author_sort Zuponcic, Jacqueline
collection PubMed
description Introduction  The United States ranks 27th among nations worldwide for infant mortality with a rate of 6.1 deaths per 1,000 live births. The majority of perinatal morbidity and mortality is related to preterm birth, defined as delivery prior to 37 weeks' gestation. Among the risk factors for preterm birth is prior preterm birth, which is associated with a 1.5- to 2.0-fold increase in risk. At the present time, there is only one Food and Drug Administration approved treatment for the prevention of preterm birth among women with a history of prior spontaneous premature delivery, intramuscular 17-α-hydroxyprogesterone caproate (17-OHP), administered once weekly from 20 to 36 weeks' gestation. However, many eligible pregnant patients decline this therapy. Methods  This was a prospective, cohort study involving patients who were identified as candidates for 17-OHP treatment at their first obstetric visit and asked to complete a short survey regarding their history of preterm birth. Those patients who consented to a follow-up phone call were asked to participate in a focus group discussion regarding their experience with progesterone and the health care system. Results  During the 1-year study period, 55 progesterone candidates were identified, 43 accepted treatment, 7 refused, and 5 either initiated prenatal care too late to receive injections or did not follow-up. Those who accepted treatment appeared to cope better with treatment side effects, and/or had traumatic emotional reactions regarding their prior premature birth outcomes. Women who declined treatment often cited pain with injection, had fatalistic beliefs regarding their care, and/or had personal concerns related to full-term pregnancy. Discussion  Maternal health care providers should always discuss the implications of prematurity at the time of the index premature delivery and again at the first prenatal visit of the subsequent pregnancy. Providers need to be prepared to employ various techniques for patient counseling and education. Small changes in office practice, like having fewer care providers involved in patient care or providing distractions for children, may make the difference between a patient who is open or closed to treatment options.
format Online
Article
Text
id pubmed-6702025
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Thieme Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-67020252019-08-21 Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery Zuponcic, Jacqueline Cottrell, Connie Lavin, Justin Facchini, Wendy Li, Marissa AJP Rep Introduction  The United States ranks 27th among nations worldwide for infant mortality with a rate of 6.1 deaths per 1,000 live births. The majority of perinatal morbidity and mortality is related to preterm birth, defined as delivery prior to 37 weeks' gestation. Among the risk factors for preterm birth is prior preterm birth, which is associated with a 1.5- to 2.0-fold increase in risk. At the present time, there is only one Food and Drug Administration approved treatment for the prevention of preterm birth among women with a history of prior spontaneous premature delivery, intramuscular 17-α-hydroxyprogesterone caproate (17-OHP), administered once weekly from 20 to 36 weeks' gestation. However, many eligible pregnant patients decline this therapy. Methods  This was a prospective, cohort study involving patients who were identified as candidates for 17-OHP treatment at their first obstetric visit and asked to complete a short survey regarding their history of preterm birth. Those patients who consented to a follow-up phone call were asked to participate in a focus group discussion regarding their experience with progesterone and the health care system. Results  During the 1-year study period, 55 progesterone candidates were identified, 43 accepted treatment, 7 refused, and 5 either initiated prenatal care too late to receive injections or did not follow-up. Those who accepted treatment appeared to cope better with treatment side effects, and/or had traumatic emotional reactions regarding their prior premature birth outcomes. Women who declined treatment often cited pain with injection, had fatalistic beliefs regarding their care, and/or had personal concerns related to full-term pregnancy. Discussion  Maternal health care providers should always discuss the implications of prematurity at the time of the index premature delivery and again at the first prenatal visit of the subsequent pregnancy. Providers need to be prepared to employ various techniques for patient counseling and education. Small changes in office practice, like having fewer care providers involved in patient care or providing distractions for children, may make the difference between a patient who is open or closed to treatment options. Thieme Medical Publishers 2019-07 2019-08-20 /pmc/articles/PMC6702025/ /pubmed/31435484 http://dx.doi.org/10.1055/s-0039-1688776 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Zuponcic, Jacqueline
Cottrell, Connie
Lavin, Justin
Facchini, Wendy
Li, Marissa
Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title_full Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title_fullStr Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title_full_unstemmed Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title_short Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
title_sort addressing decision making in progesterone treatment for history of preterm delivery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702025/
https://www.ncbi.nlm.nih.gov/pubmed/31435484
http://dx.doi.org/10.1055/s-0039-1688776
work_keys_str_mv AT zuponcicjacqueline addressingdecisionmakinginprogesteronetreatmentforhistoryofpretermdelivery
AT cottrellconnie addressingdecisionmakinginprogesteronetreatmentforhistoryofpretermdelivery
AT lavinjustin addressingdecisionmakinginprogesteronetreatmentforhistoryofpretermdelivery
AT facchiniwendy addressingdecisionmakinginprogesteronetreatmentforhistoryofpretermdelivery
AT limarissa addressingdecisionmakinginprogesteronetreatmentforhistoryofpretermdelivery